uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
← catalyst calendarSponsored by UroGen Pharma Ltd. (industry) · URGN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
400estimated
Sites
22
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-17 | actual | When the study began enrolling |
| Primary completion | Apr 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Urothelial Carcinoma
- Urothelial Carcinoma Recurrent
- Urothelial Carcinoma Ureter
- Urothelial Carcinoma Ureter Recurrent
- Urothelial Cancer of Renal Pelvis
- Urothelial Carcinoma of the Renal Pelvis and Ureter
- Carcinoma, Transitional Cell
- Transitional Cell Carcinoma of Renal Pelvis
Intervention
- Drug: Jelmyto (mitomycin) for pyelocalyceal solution — also filed as Jelmyto, UGN-101
Primary outcome
what the primary-completion date above is the date OFRate of CR or no evidence of disease (NED) at first evaluation post-treatment
measured 3 months
Permalink · URGN's whole pipeline · Catalyst calendar · Every registered study · What changed